Next-Generation Therapeutic Strategies for Relapsed/Refractory Multiple Myeloma: Targeting BCMA

Experts discuss how they incorporate BCMA-targeted agents into the treatment of patients with MM and manage toxicities associated with these agents. This program features ClinicalThought commentaries downloadable slides and an on-demand webcast from a live webinar.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Supporters

Supported by educational grants from

GlaxoSmithKline

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC